AnaptysBio, Inc. (NASDAQ:ANAB) Sees Significant Increase in Short Interest

AnaptysBio, Inc. (NASDAQ:ANAB) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 6,710,000 shares, a growth of 8.6% from the October 31st total of 6,180,000 shares. Based on an average trading volume of 403,100 shares, the short-interest ratio is currently 16.6 days. Approximately 25.8% of the company’s stock are short sold.

Insider Activity

In other AnaptysBio news, insider Eric J. Loumeau sold 8,720 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.82, for a total transaction of $347,230.40. Following the sale, the insider now directly owns 7,020 shares in the company, valued at $279,536.40. The trade was a 55.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock worth $892,936 over the last ninety days. Corporate insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Institutional investors have recently modified their holdings of the company. Values First Advisors Inc. acquired a new stake in AnaptysBio in the 3rd quarter valued at about $49,000. nVerses Capital LLC lifted its stake in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Headlands Technologies LLC grew its position in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after buying an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 2,600 shares in the last quarter. Finally, Point72 DIFC Ltd lifted its position in shares of AnaptysBio by 680.5% during the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 5,342 shares during the last quarter.

AnaptysBio Stock Up 10.0 %

ANAB stock traded up $2.21 during trading on Wednesday, reaching $24.21. 240,170 shares of the company’s stock were exchanged, compared to its average volume of 357,622. The firm has a market cap of $736.69 million, a PE ratio of -3.86 and a beta of -0.11. AnaptysBio has a 1-year low of $14.75 and a 1-year high of $41.31. The company’s fifty day moving average price is $27.65 and its 200-day moving average price is $29.72.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. As a group, sell-side analysts expect that AnaptysBio will post -6.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. UBS Group lifted their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. HC Wainwright lowered their price target on AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. JPMorgan Chase & Co. dropped their price target on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Truist Financial lifted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, Wedbush reissued an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.